射血分数降低的心力衰竭患者病情恶化的临床病程
本研究基于美国PINNACLE注册数据库链接药房、私人执业和医院索赔数据,评估真实世界中射血分数降低的心力衰竭(HFrEF)患者发生病情恶化(定义为稳定≥90天后需要静脉利尿剂)的发病率、临床特征、治疗和结局。在11,064例HFrEF患者中,1,851例(17%)在初始诊断后平均1.5年发生恶化,2年死亡率为22.5%,56%在恶化事件后30天内再住院,标准治疗使用率低。
要点
- 真实世界中约1/6的HFrEF患者在诊断后18个月内发生病情恶化。
- 恶化HF患者2年死亡率达22.5%,30天内再住院率高达56%。
- 恶化HF前后标准治疗(ACEI/ARB、β受体阻滞剂、MRA)使用率低。
核心结论
- 真实世界中,每6例HFrEF患者中约有1例在诊断后18个月内发生病情恶化,且这些患者2年死亡和再住院风险高,标准治疗使用不足。
研究设计与样本
- 基于美国国家心血管数据注册PINNACLE中新发HFrEF患者,链接药房、私人执业和医院索赔数据库,评估恶化HF(稳定≥90天后需要静脉利尿剂)的发病率、特征、治疗和结局。
- 共纳入11,064例HFrEF患者,其中1,851例(17%)发生恶化HF。
主要发现
- 恶化HF患者更可能为非裔美国人、八十多岁且合并症负担更高(p < 0.001)。
- 恶化HF发生时,42.4%患者接受单药治疗,43.4%接受双药治疗,14.1%接受三联治疗。
- 48%、61%和98%的患者分别接受ACEI/ARB、β受体阻滞剂和MRA剂量超过目标剂量50%的治疗。
- 2年死亡率为22.5%,56%的患者在恶化HF事件后30天内再住院。
临床怎么用
- 临床应识别HFrEF患者中病情恶化高风险人群,并加强指南指导的药物治疗的优化。
- 恶化HF事件后需关注高再住院和死亡风险,考虑新型治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epidemiology of patients with worsening heart failure and reduced ejection fraction (HFrEF) in the real-world setting is not well described. OBJECTIVES: The purpose of this study was to describe incidence, clinical characteristics, treatment, and outcomes of patients with HFrEF who develop worsening heart failure (HF) in the real-world setting. METHODS: Data on patients with incident HFrEF from the National Cardiovascular Data Registry PINNACLE were linked to pharmacy, private practitioner, and hospital claims databases. Incidence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of patients with worsening HF, defined as ≥90 days of stable HF with subsequent worsening requiring intravenous diuretic agents, were assessed. RESULTS: Of 11,064 HFrEF patients, 1,851 (17%) developed worsening HF on average 1.5 years following initial HF diagnosis. Patients who developed worsening HF were more likely to be African American, be octogenarians, and have higher comorbidity burden (p < 0.001). At the onset of worsening HF, 42.4% of patients were on monotherapy, 43.4% were on dual therapy, and 14.1% were on triple therapy. A total of 48%, 61%, and 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively. The 2-year mortality rate was 22.5%, and 56% of patients were rehospitalized within 30 days of the worsening HF event. CONCLUSIONS: In the real-world setting, 1 in 6 patients with HFrEF develop worsening HF within 18 months of HF diagnosis. These patients have a high risk for 2-year mortality and recurrent HF hospitalizations. The use of standard-of-care therapies both before and after the onset of worsening HF is low. With high unmet medical need, patients with worsening HF require novel treatment strategies as well as greater optimization of existing guideline-directed therapy.
引用
- Butler J, Yang M, Manzi MA, et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019. PMID: 30819362. doi:10.1016/j.jacc.2018.11.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。